NEW YORK (GenomeWeb News) — Rosetta Genomics has struck an agreement to use some of Rockefeller University’s viral and human microRNAs for therapeutic uses, the company said Wednesday.

 

Rosetta Genomics President and CEO Amir Avniel said the microRNAs offer the company access to more potential drug targets, and is in line with the its strategy to supplement its own research through licensing agreements with key academic centers. 

 

The company said it now has the rights to more than 500 microRNA targets.